Merck cancer drug cuts death risk 32% in late-stage trial

Merck’s sac-TMT cut death risk by 32% in a late-stage endometrial cancer trial, extending median survival to 19 months. The FDA accepted the drug for priority review, with a decision expected by June 2027.